CD274 and neoplasm: These neoantigens recognized by activated anti-tumor T-cell repertoire have been shown to correlate with response to PD-L1/PD-1 antibodies in a range of advanced solid tumors, including advanced BC carcinoma and could be explored for novel immunotherapy approaches [34].